摘要
筛选可转化抗肿瘤新药XC302的微生物菌种,并对转化产物和活性进行研究。利用保藏的植物内生真茵进行转化筛选,获得了一株具有转化XC302能力的真茵HCCB07927,经过分子生物学鉴定,该茵属于丝核茵属(Rhizoctonm),该菌株可转化XC302生成两个转化产物LYBXYl、LYBXY2。经MS-MS分析初步确定了两个化舍物的结构。抗肿瘤活性测定表明,两个产物均对PANC-1细胞具有较高的抑制作用,其抑制率高于对照品XC302。通过微生物转化技术,成功获得两个转化产物,其均对PANC-1细胞具有较高抑制活性。
In order to obtain the derivatives of new anti-tumor medicine XC302, a strain HCCB07927 with the ability of converting XC302 was screened from endophytes, which was identified as Rhizoctonia taxonomically. The transformation products of XC302 were named LYBXY1 and LYBXY2. The structures of the compounds were evaluated by MS-MS. Both of them had an inhibitory action against PANC-1, and the inhibition rate against PANC-1 was higher than that of XC302. Using the biotransformation technology, the derivatives of the XC302 were successfully obtained.
出处
《工业微生物》
CAS
CSCD
2014年第2期20-24,共5页
Industrial Microbiology
基金
国家重大新药创制专项资助(2008ZX09401)
关键词
微生物转化
真菌筛选
结构鉴定
抗肿瘤
microbial transformation
screening
identification
anti-tumor
